肝胆相照论坛

标题: HBsAg，HBcrAg和肝细胞癌之间的关系在患者检测不到HBV DNA核苷 [打印本页]

作者: StephenW 时间: 2017-2-13 21:27 标题: HBsAg，HBcrAg和肝细胞癌之间的关系在患者检测不到HBV DNA核苷

J Viral Hepat. 2017 Feb 10. doi: 10.1111/jvh.12688. [Epub ahead of print]
Complete title: Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.Cheung KS1, Seto WK1,2, Wong DK1,2, Lai CL1,2, Yuen MF1,2.
Author information

1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
2State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.

AbstractWe examined the relationship between hepatitis B surface and core-related antigens (HBsAg, HBcrAg) and hepatocellular carcinoma (HCC) development in patients with undetectable serum HBV DNA receiving nucleos(t)ide analogue (NA). Seventy-six HBV carriers with undetectable HBV DNA (<20 IU/mL) who subsequently developed HCC were compared with 152 matched controls. Clinical and laboratory parameters (including novel assays to measure linearized HBsAg [HQ-HBsAg] and HBcrAg) were analyzed. There were no significant differences in HBsAg/ HQ-HBsAg levels between the two groups. There was a significant difference in the median values of both pre- and post-NA HBcrAg levels between the HCC and control groups (pre-treatment: 279.0 vs 35.4 kU/mL, p=0.005; post-treatment: 10.2 vs 1.7 kU/mL, p=0.005, respectively). For the whole HCC group, a cutoff value of post-treatment HBcrAg level ≥7.8 kU/mL yielded an area under receiver operating curve (AUROC) of 0.61 with a negative predictive value (NPV) of 77.0%. The OR of HCC development was 3.27. For non-cirrhotic patients, the median values of post-treatment HBcrAg level of HCC group and controls were 10.2 and 1.0 kU/mL respectively (p=0.001). A cutoff value of HBcrAg level ≥7.9 kU/mL yielded an AUROC of 0.70 with a NPV of 80.6%. The OR of HCC development was 5.95. A higher pre- and post-NA treatment HBcrAg level (but not HBsAg) was associated with an increased risk of HCC development in patients achieving undetectable serum HBV DNA while on NA therapy. HBcrAg may serve as a novel risk marker for HCC in this group of patients. This article is protected by copyright. All rights reserved.

KEYWORDS: HCC; NA therapy; hepatitis B core-related antigen

PMID:28185363DOI:10.1111/jvh.12688

作者: StephenW 时间: 2017-2-13 21:28

J病毒Hepat。 2017年2月10日。doi：10.1111 / jvh.12688。 [印刷前电子版]
完整标题：HBsAg，HBcrAg和肝细胞癌之间的关系在患者检测不到HBV DNA核苷（t）ide治疗。
Cheung KS1，Seto WK1,2，Wong DK1,2，Lai CL1,2，Yuen MF1,2。
作者信息

1香港大学医学院，香港玛丽医院。
2香港大学肝脏研究国家重点实验室。

抽象

我们检查了乙型肝炎表面和核心相关抗原（HBsAg，HBcrAg）和肝细胞癌（HCC）发展的不可检测的血清HBV DNA接受核苷酸类似物（NA）之间的关系。随后发展HCC的七十六个具有不可检测的HBV DNA（<20IU / mL）的HBV载体与152个匹配的对照进行比较。分析了临床和实验室参数（包括测量线性化HBsAg [HQ-HBsAg]和HBcrAg的新测定法）。两组之间HBsAg / HQ-HBsAg水平无显着差异。在HCC和对照组之间的前和后NA HBcrAg水平的中值的中值有显着差异（治疗前：279.0对35.4kU / mL，p = 0.005;后处理：10.2对1.7kU / mL，p = 0.005）。对于整个HCC组，治疗后HBcrAg水平≥7.8kU / mL的截断值产生的受试者工作曲线下面积（AUROC）为0.61，阴性预测值（NPV）为77.0％。 HCC发展的OR为3.27。对于非肝硬化患者，HCC组和对照的治疗后HBcrAg水平的中值分别为10.2和1.0 kU / mL（p = 0.001）。 HBcrAg水平≥7.9kU / mL的截断值产生的AUROC为0.70，NPV为80.6％。 HCC发展的OR为5.95。较高的前和后NA处理HBcrAg水平（但不是HBsAg）与在NA治疗时获得不可检测的血清HBV DNA的患者中HCC发展的风险增加相关。 HBcrAg可作为这组患者中HCC的新型风险标志物。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

HCC; NA治疗;乙型肝炎核心相关抗原

PMID：
28185363
DOI：
10.1111 / jvh.12688

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)